NCT07463768: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Sponsor: French Innovative Leukemia Organisation. Phase: PHASE2. Conditions: Acute Myeloid Leukemia